The proposed expansion involves adding a second phase, designated as Part B, to the REO-033 clinical trial. Leadership at Oncolytics aims to leverage this structure to facilitate both accelerated and traditional approval pathways within a single study. This strategic pivot comes as the company reports steady momentum in its research infrastructure.
In section Market Quotes
Oncolytics Biotech Stock Climbs on FDA Meeting and Trial Expansion
Investors pushed Oncolytics Biotech shares up 16% to $1.03 on Monday morning following the company's announcement of a critical FDA meeting scheduled for August. The discussion will center on integrating a registrational component into the ongoing study targeting RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Operational progress remains on schedule, with approximately half of the planned clinical centers slated for activation throughout July. Oncolytics expects to bring additional sites online by the end of August, supported by a recruitment pipeline that has already pre-identified more than 20 patients across participating medical centers.
Comments (0)
No comments yet. Be the first!